Palbociclib (Ibrance®, Pfizer, New York, NY, USA) was approved by the FDA in 2015 for the treatment of postmenopausal women with hormone HR+, HER2− metastatic advanced breast cancer in combination with letrozole following the results of a phase III study, PALOMA-2. This evidence concerns the gene HR and breast cancer.